NEW YORK, October 23, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding CVS Health Corporation (NYSE: CVS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Allergan Inc. (NYSE: AGN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7418-100free.
CVS Health Corporation Research Reports
On October 16, 2014, CVS Health Corporation's retail division CVS/pharmacy announced that it will offer its senior patients an easy way to compare Medicare Part D prescription drug plans during the Annual Enrollment Period of October 15 to December 7, 2014. "CVS/pharmacy's plan comparison tool provides patients with convenient ways to learn how much money they could save by choosing a new Medicare Part D plan based on their own prescription usage," said Josh Flum, Senior Vice President of Retail Pharmacy, CVS Health. The full research reports on CVS are available to download free of charge at:
Valeant Pharmaceuticals International, Inc. Research Reports
On October 20, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) announced its Q3 2014 financial results. The Company reported revenues for the quarter at $2.1 billion, up 33.4% YoY. Valeant's revenues from the developed markets were up 32% YoY at $1.5 billion, while emerging markets revenue increased 37.4% YoY at $548.3 million. Net income attributable to Valeant increased to $275.4 million, or $0.81 per diluted share, in Q3 2014, compared with a loss of $973.2 million or $2.92 per diluted share in Q3 2013. Cash EPS of the Company stood at $2.11, beating the average estimates of $1.99 in a Reuters poll of analysts. The Company's stock jumped 3.80% to close at $124.78. According to a Reuters report, Valeant may also raise its bid for Botox maker Allergan Inc. to more than $200 per share from the current bid of about $52.7 billion or $176.00 per share. The full research reports on Valeant are available to download free of charge at:
Regeneron Pharmaceuticals, Inc. Research Reports
On October 20, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi jointly announced the initiation of Phase-3 study of Dupilumab in patients with Atopic Dermatitis (AD) that is not adequately controlled with topical AD medications. Dupilumab, an investigational therapy that blocks IL-4 and IL-13, was created using Regeneron's pioneering VelocImmune® technology and is being co-developed with Sanofi in atopic dermatitis, asthma and chronic sinusitis with nasal polyposis. The Company informed that the LIBERTY AD Phase 3 clinical program will consist of at least five trials of patients with moderate-to-severe AD at sites worldwide. "This Phase 3 program will evaluate if blocking IL-4 and IL-13, two key cytokines in the Th2 inflammatory pathway, may provide a potential new approach for this chronic, difficult-to-manage disease," said Donald Y. M. Leung, MD, PhD, a member of the LIBERTY AD Clinical Trials Steering Committee and Head of the Division of Pediatric Allergy and Immunology at National Jewish Health in Denver, Colorado. The full research reports on Regeneron are available to download free of charge at:
Allergan Inc. Research Reports
On October 20, 2014, Reuters reported that Allergan Inc.'s (Allergan's) one of the top shareholders Paulson & Co is urging the Company to merge with Shire plc (Shire) as an alternative to Valeant Pharmaceuticals' hostile bid. According to the report, Paulson & Co had a 1.9% stake in Allergan as of June 30, 2014. Paulson also had a 1.7% stake in Shire as of June 30, 2014, the report said. Reuters pointed that the move comes at a time when Allergan is struggling to avoid hostile takeover by Valeant. Also, it comes at a time when Shire's proposed merger deal with AbbVie fell apart recently owing to the U.S. government's new rules that seeks to make so-called tax inversion deal difficult for companies. On the same day, Allergan's stock rose 0.99% to close at $179.25. The full research reports on Allergan are available to download free of charge at:
Agilent Technologies Inc. Research Reports
On October 20, 2014, Agilent Technologies Inc. (Agilent) announced the launch of the SureSelect Focused Exome, a target enrichment solution that enables deep coverage of only those target regions that have been associated with disease. The Company informed that the latest design is 16 Mb in size and enables 98% of targeted regions to be covered with 20 or more reads with only 3 Gb of sequencing, allowing for sensitive detection of variants within a given sample. Agilent's SureSelect Focused Exome enables clinical researchers to confidently make variant calls in regions of significance by targeting regions defined in HGMD, OMIM and ClinVar databases. The full research reports on Agilent are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review